This Article Full Text (PDF) CME: Take the course for this article: Evaluation of Vitamin D Deficiency in Breast Cancer Patients on Bisphosphon... All Versions of this Article: theoncologist.2008-0013v1 13/7/821    most recent eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Google Scholar Articles by Wang-Gillam, A. Articles by Hutchins, L. F. PubMed PubMed Citation Articles by Wang-Gillam, A. Articles by Hutchins, L. F.

Evaluation of Vitamin D Deficiency in Breast Cancer Patients on Bisphosphonates

^aDivision of Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA; ^bDivision of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

Key Words. Vitamin D deficiency • Breast cancer • Bisphosphonates • 25-Hydroxyvitamin D • Hyperparathyroidism

Correspondence: Correspondence: Laura F. Hutchins, M.D., Division of Hematology/Oncology, Slot 508, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA. Telephone: 501-686-8511; Fax: 501-686-6342; e-mail: HutchinsLauraF{at}uams.edu

Received January 15, 2008; accepted for publication April 14, 2008.

ABSTRACT

Background. Bisphosphonates are very effective in treating osteoporosis and metastatic bone disease; however, unfavorable outcomes can occur when they are given to patients with occult vitamin D deficiency. No clear consensus exists on the assessment of vitamin D status in cancer patients undergoing bisphosphonate therapy. This study examines the prevalence of vitamin D deficiency among breast cancer patients treated with bisphosphonates for osteoporosis or metastatic bone disease, and observes the use of calcium and vitamin D supplementation in these patients.

Methods. This retrospective study reviewed the electronic records of 321 breast cancer patients treated with bisphosphonates. Information on age, race, and serum levels of 25-hydroxyvitamin D (25-OHD), parathyroid hormone, and calcium were collected, and intakes of calcium and vitamin D supplements were queried in an outpatient pharmacy database.

Results. Of the 321 patients treated with bisphosphonates, 209 (65.1%) had their 25-OHD levels checked at least once. Of these patients, 57 (27.3%) had a serum 25-OHD level <20 ng/ml. Of the 209 patients with a known 25-OHD level, only eight (3.8%) received >600 IU of vitamin D per day, and 41 (19.6%) patients received 400–600 IU of vitamin D daily.

Conclusion. Especially in the setting of metastatic bone disease in breast cancer patients, we advocate routine 25-OHD concentration screening for vitamin D deficiency in general. Clear guidelines for the diagnosis of vitamin D deficiency in cancer patients would be extremely beneficial to have, as would identification of the proper dose of vitamin D supplementation. We recommend 1,000 IU daily to our metastatic cancer patients.